Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting

Diabetes, Obesity and Metabolism

Volumn 14, Issue 7, 2012, Pages 626-633

  Pawaskar, M ^a   Li, Q ^b   Hoogwerf, B J ^a   Reynolds, M W ^b   Faries, D ^a   Engelman, W ^b   Bruhn, D ^a   Bergenstal, R M ^c  

^a ELI LILLY AND COMPANY   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c INTERNATIONAL DIABETES CENTER   (United States)

Author keywords

Clinical effectiveness; Exenatide BID; Glargine

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN GLARGINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AMBULATORY CARE; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

EID: 84862777529     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01581.x     Document Type: Article

References (26)

1. Byetta (exenatide) [package insert]. Prescribing information. San Diego, CA: Amylin Pharmaceuticals, Inc., 2010. Available from URL: Accessed 27 February 2012.
2. Robles GI, Singh-Franco D. A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther 2009; 3: 219-240.
3. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286.
4. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.
5. Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333-2348.
6. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009; 11: 1153-1162.
7. Bunck MC, Diamant M, Corner A et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762-768.
8. Bunck MC, Diamant M, Eliasson B et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010; 33: 1734-1737.
9. Bunck MC, Corner A, Eliasson B et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010; 212: 223-229.
10. Varanasi A, Chaudhuri A, Dhindsa S et al. Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. Endocr Pract 2011; 17: 192-200.
11. De Block C, Paquot N, Daoudi N, Ballaux D, Van Gaal LF, Scheen AJ. [Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study]. Rev Med Liege 2009; 64: 488-495.
12. Bhushan R, Elkind-Hirsch KE, Bhushan M, Butler WJ, Duncan K, Marrioneaux O. Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes Technol Ther 2009; 11: 353-359.
13. Buysschaert M, Preumont V, Oriot PR et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab 2010; 36: 381-388.
14. Brixner DI, McAdam-Marx C, Ye X et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab 2009; 11: 1122-1130.
15. Fabunmi R, Nielsen LL, Quimbo R et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009; 25: 777-786.
16. Pawaskar M, Zagar A, Sugihara T, Shi L. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis. J Med Econ 2011; 14: 16-27.
17. Misurski D, Lage MJ, Fabunmi R, Boye KS. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Appl Health Econ Health Policy 2009; 7: 245-254.
18. Brixner DI, Said Q, Kirkness C, Oberg B, Ben-Joseph R, Oderda G. Assessment of cardiometabolic risk factors in a national primary care electronic health record database. Value Health 2007; 10: S29-36.
19. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34(Suppl. 1): S11-61.
20. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
21. LaLonde R. Evaluating the econometric evaluations of training programs. Am Econ Rev 1986; 76: 604-620.
22. Dehejia RH, Wahba S. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Stat 2002; 84: 151-161.
23. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008; 27: 2037-2049.
24. LANTUS® [package insert]. Prescribing information (insulin glargine [rDNA origin] injection). Bridgewater, NJ: Sanofi-aventis U.S. LLC, 2007. Available from URL: Accessed 27 February 2012.
25. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010; 33: 1759-1765.
26. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.